Bin Hameed Usman, Karsten Joel, Banno Fady, Nadeau Brian
Internal Medicine, Corewell Health William Beaumont University Hospital, Royal Oak, USA.
Internal Medicine, Oakland University William Beaumont School of Medicine, Auburn Hills, USA.
Cureus. 2025 May 27;17(5):e84888. doi: 10.7759/cureus.84888. eCollection 2025 May.
Sickle cell disease (SCD) is a genetic disorder characterized by chronic hemolytic anemia and multi-organ dysfunction. The liver is frequently affected in SCD, with complications spanning from mild hyperbilirubinemia to acute liver failure. Acute hepatic sequestration (AHS), a rare but serious manifestation of sickle cell hepatopathy, can rapidly progress to multi-organ dysfunction syndrome (MODS). Cases with extreme hyperbilirubinemia (bilirubin > 20 mg/dL) remain exceptionally uncommon. A 19-year-old female patient with SCD presented with nausea, vomiting, generalized pain, dysuria, and suprapubic pain. On presentation, her vital signs were stable except for tachycardia (139 beats per minute (bpm)). Physical examination revealed scleral icterus, conjunctival pallor, and right upper quadrant (RUQ) tenderness. Initial laboratory results showed leukocytosis (white blood cell (WBC): 22.7 bil/L), hemoglobin (Hb) of 7.5 g/dL (baseline: 8.5 g/dL), and platelet (PLT) of 178 bil/L. Lactate dehydrogenase (LDH) was at 734 U/L. Liver function tests showed alkaline phosphatase (ALP) at 238 IU/L, aspartate transaminase (AST) at 52 U/L, alanine transaminase (ALT) at 49 U/L, and total bilirubin at 13.4 mg/dL. Abdominal ultrasound showed hepatomegaly (liver span of 19 cm) and gallstones without signs of cholecystitis. Blood cultures (2/2) tested positive for (). Initial management included intravenous (IV) fluids, pain control, IV antibiotics, and two units of packed red blood cells (RBCs). Despite treatment, total bilirubin rose to 35.1 mg/dL with direct bilirubin at >15 mg/dL, hemoglobin dropped to 5.5 g/dL, and platelet count decreased to 124 bil/L. An elevated reticulocyte count (295 × 10⁹/L) and percentage (10.47%) confirmed hepatic sequestration. Exchange transfusion improved the percentage of hemoglobin S (HbS) from 58.9% to 23.4%, decreased bilirubin levels to 12.1 mg/dL, and alleviated symptoms. AHS is rare, occurring in about 1.5% of SCD patients. Extreme hyperbilirubinemia in this case (total bilirubin of 35.1 mg/dL) was more severe than usually seen in AHS, reflecting the severity of the clinical presentation. Differentiating AHS from other hepatic complications, such as acute sickle cell hepatic crisis (ASCHC) and acute intrahepatic cholestasis (AIC), is crucial due to differing management approaches. While ASCHC often responds to supportive care, AHS may require urgent transfusion, and AIC might necessitate invasive interventions, including liver transplantation. Exchange transfusion is effective in AHS by rapidly reducing HbS levels, improving hepatic function, and preventing progression to MODS. Given that AHS is a rare but critical complication of SCD, this case highlights the importance of prompt recognition, a high index of suspicion, and early intervention to optimize outcomes in severe SCD-related hepatic complications.
镰状细胞病(SCD)是一种遗传性疾病,其特征为慢性溶血性贫血和多器官功能障碍。肝脏在SCD中常受影响,并发症范围从轻度高胆红素血症到急性肝衰竭。急性肝内血液滞留(AHS)是镰状细胞性肝病的一种罕见但严重的表现,可迅速进展为多器官功能障碍综合征(MODS)。极度高胆红素血症(胆红素>20mg/dL)的病例仍然极为罕见。一名19岁的SCD女性患者出现恶心、呕吐、全身疼痛、排尿困难和耻骨上疼痛。就诊时,除心动过速(139次/分钟(bpm))外,她的生命体征稳定。体格检查发现巩膜黄染、结膜苍白和右上腹(RUQ)压痛。初始实验室检查结果显示白细胞增多(白细胞(WBC):22.7×10⁹/L),血红蛋白(Hb)为7.5g/dL(基线:8.5g/dL),血小板(PLT)为178×10⁹/L。乳酸脱氢酶(LDH)为734U/L。肝功能检查显示碱性磷酸酶(ALP)为238IU/L,天冬氨酸转氨酶(AST)为52U/L,丙氨酸转氨酶(ALT)为49U/L,总胆红素为13.4mg/dL。腹部超声显示肝肿大(肝径19cm)和胆结石,无胆囊炎迹象。血培养(2次均)检测到(此处原文缺失具体病菌信息)呈阳性。初始治疗包括静脉输液、疼痛控制、静脉使用抗生素以及两单位浓缩红细胞(RBC)。尽管进行了治疗,总胆红素升至35.1mg/dL,直接胆红素>15mg/dL,血红蛋白降至5.5g/dL,血小板计数降至124×10⁹/L。网织红细胞计数升高(295×10⁹/L)和百分比升高(10.47%)证实了肝内血液滞留。换血治疗使血红蛋白S(HbS)百分比从58.9%降至23.4%,胆红素水平降至12.1mg/dL,并缓解了症状。AHS很罕见,约1.5%的SCD患者会发生。该病例中的极度高胆红素血症(总胆红素35.1mg/dL)比AHS通常所见更为严重,反映了临床表现的严重性。由于治疗方法不同,将AHS与其他肝脏并发症,如急性镰状细胞性肝危象(ASCHC)和急性肝内胆汁淤积(AIC)区分开来至关重要。虽然ASCHC通常对支持治疗有反应,但AHS可能需要紧急输血,而AIC可能需要包括肝移植在内的侵入性干预措施。换血治疗通过迅速降低HbS水平、改善肝功能以及防止进展为MODS,对AHS有效。鉴于AHS是SCD一种罕见但严重的并发症,该病例突出了及时识别、高度怀疑指数以及早期干预对于优化严重SCD相关肝脏并发症结局的重要性。